Jazz Pharmaceuticals announced it will present 21 abstracts, including 11 late-breaking ones, at the SLEEP 2026 conference, highlighting new research on its low-sodium oxybate treatment, Xywav, for narcolepsy and idiopathic hypersomnia. The data focus on improving patient outcomes, including sleep inertia and daytime symptoms, with real-world evidence supporting Xywav's safety and efficacy. This presentation underscores Jazz's commitment to advancing therapies for rare sleep disorders and may influence future treatment approaches. The abstracts will be available online during the conference in June 2026.
The US government is actively negotiating to take equity stakes in AI companies like OpenAI and Anthropic ahead of their planned IPOs, following a precedent set by its investment in Intel. This move aims to give the public a share in AI-driven growth...
Trulieve Cannabis Corp. made history by becoming the first U.S. cannabis company to list on the New York Stock Exchange under the ticker TRLV. This milestone was enabled by the Trump administration's reclassification of cannabis to Schedule III for m...
West Fraser Timber Co. Ltd. announced a quarterly dividend of US$0.32 per share on its Common and Class B Common shares. The dividend will be paid on July 13, 2026, to shareholders of record as of June 25, 2026. Shareholders have the option to receiv...
BIO-key International, a leader in biometric authentication, received a Nasdaq notice for failing to file its quarterly 10-Q report on time for Q1 2026. Nasdaq's notice indicates the company's compliance with listing rules is under review, and a hear...
Nyxoah SA has issued 55,232,558 new ordinary shares as part of a previously announced public offering, increasing the total number of shares with voting rights to 99,926,284. This move follows a private placement to qualified investors outside the U....
